During the last session, Leap Therapeutics Inc. (NASDAQ:LPTX)’s traded shares were 1.69 million, with the beta value of the company hitting 0.63. At the end of the trading day, the stock’s price was $0.79, reflecting an intraday loss of -3.78% or -$0.03. The 52-week high for the LPTX share is $1.86, that puts it down -135.44 from that peak though still a striking 65.82% gain since the share price plummeted to a 52-week low of $0.27. The company’s market capitalization is $92.74M, and the average intraday trading volume over the past 10 days was 1.89 million shares, and the average trade volume was 778.62K shares over the past three months.
Leap Therapeutics Inc. (LPTX) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.80. LPTX has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 2 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.09.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Leap Therapeutics Inc. (NASDAQ:LPTX) trade information
Leap Therapeutics Inc. (LPTX) registered a -3.78% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -3.78% in intraday trading to $0.79 this Wednesday, 05/24/23, hitting a weekly high. The stock’s 5-day price performance is 29.37%, and it has moved by 119.17% in 30 days. Based on these gigs, the overall price performance for the year is -30.79%. The short interest in Leap Therapeutics Inc. (NASDAQ:LPTX) is 11.51 million shares and it means that shorts have 18.28 day(s) to cover.
The consensus price target of analysts on Wall Street is $2.50, which implies an increase of 68.4% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2.00 and $3.00 respectively. As a result, LPTX is trading at a discount of -279.75% off the target high and -153.16% off the low.
Leap Therapeutics Inc. (LPTX) estimates and forecasts
Statistics show that Leap Therapeutics Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Leap Therapeutics Inc. (LPTX) shares have gone up 33.68% during the last six months, with a year-to-date growth rate less than the industry average at -18.75% against 11.40. Yet analysts are ramping up their growth forecast for the fiscal year 2023. Revenue is predicted to grow 40.00% this quarter and then jump 46.20% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 36.00%. While earnings are projected to return -2.00% in 2023, the next five years will return -2.49% per annum.
Leap Therapeutics Inc. is due to release its next quarterly earnings between August 10 and August 14. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Leap Therapeutics Inc. (NASDAQ:LPTX)’s Major holders
Leap Therapeutics Inc. insiders own 8.28% of total outstanding shares while institutional holders control 33.60%, with the float percentage being 36.63%. Baker Brothers Advisors, LLC is the largest shareholder of the company, while 69 institutions own stock in it. As of Mar 30, 2023, the company held over 7.43 million shares (or 6.22% of all shares), a total value of $5.86 million in shares.
The next largest institutional holding, with 6.73 million shares, is of Perceptive Advisors Llc’s that is approximately 5.63% of outstanding shares. At the market price on Mar 30, 2023, these shares were valued at $5.31 million.
Also, the Mutual Funds coming in first place with the largest holdings of Leap Therapeutics Inc. (LPTX) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Dec 30, 2022 indicates that Vanguard Total Stock Market Index Fund owns about 2.29 million shares. This amounts to just over 1.92 percent of the company’s overall shares, with a $1.81 million market value. The same data shows that the other fund manager holds slightly less at 0.85 million, or about 0.71% of the stock, which is worth about $0.67 million.